Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer.

[1]  M. Loda,et al.  Kallikrein 4 is a Predominantly Nuclear Protein and Is Overexpressed in Prostate Cancer , 2004, Cancer Research.

[2]  Gordon B Mills,et al.  Overexpression of kallikrein 10 in epithelial ovarian carcinomas. , 2003, Gynecologic oncology.

[3]  Enrica Martinelli,et al.  Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. , 2003, Molecular pharmacology.

[4]  L. Wilkens,et al.  Stage at diagnosis of ovarian cancer in the United States, 1992–1997 , 2003, Cancer.

[5]  J. Clements,et al.  Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  E. Steiner,et al.  p53 expression and resistance against paclitaxel in patients with metastatic breast cancer , 2003, Journal of Cancer Research and Clinical Oncology.

[7]  J. Kigawa,et al.  Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. , 2002, Gynecologic oncology.

[8]  D. Katsaros,et al.  Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. , 2001, Cancer research.

[9]  D. Katsaros,et al.  Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  H. Samaratunga,et al.  Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  T. Pretlow,et al.  Distinctly different gene structure of KLK4/KLK-L1/prostase/ARM1 compared with other members of the kallikrein family: intracellular localization, alternative cDNA forms, and Regulation by multiple hormones. , 2001, DNA and cell biology.

[12]  F. Zunino,et al.  A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes , 2001, International journal of cancer.

[13]  D. Katsaros,et al.  Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer , 2001, British Journal of Cancer.

[14]  G. Yousef,et al.  Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. , 2000, Clinical biochemistry.

[15]  T. Pretlow,et al.  An efficient procedure for cloning hormone-responsive genes from a specific tissue. , 2000, DNA and cell biology.

[16]  G. Yousef,et al.  Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. , 1999, Cancer research.

[17]  K. Shigemasa,et al.  Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. , 1999, Cancer research.

[18]  J. Clements,et al.  Localization of a New Prostate-specific Antigen-related Serine Protease Gene, KLK4, Is Evidence for an Expanded Human Kallikrein Gene Family Cluster on Chromosome 19q13.3–13.4* , 1999, The Journal of Biological Chemistry.

[19]  L. Hood,et al.  Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G. Dunnington,et al.  MDR1 gene expression in primary and advanced breast cancer. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[21]  H. Earl,et al.  Chemotherapy for ovarian cancer--a consensus statement on standard practice. , 1998, British Journal of Cancer.

[22]  S. Cannistra,et al.  BAX protein expression and clinical outcome in epithelial ovarian cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[24]  Y. Miyagi,et al.  Differential expression of trypsin in human ovarian carcinomas and low-malignant-potential tumors. , 1998, Gynecologic oncology.

[25]  K. Shigemasa,et al.  Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. , 1997, Cancer research.

[26]  J. Reed,et al.  Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells , 1997, Breast Cancer Research and Treatment.

[27]  C. Runowicz,et al.  Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  M. Schiff,et al.  Ovarian cancer incidence and mortality in American Indian, Hispanic, and non-Hispanic white women in New Mexico. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[29]  H E Lambert,et al.  Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Cannistra.  Cancer of the ovary. , 1993, The New England journal of medicine.

[31]  S. Rubin,et al.  Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  O. Itkonen,et al.  Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2. , 1990, Cancer research.

[33]  W. Mellado,et al.  Taxol: Mechanisms of Action and Resistance a , 1986, Journal of the National Cancer Institute. Monographs.

[34]  S. Brenner,et al.  Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly , 1983, The Journal of cell biology.

[35]  M. Tsuda,et al.  An association of Bcl‐2 phosphorylation and Bax localization with their functions after hyperthermia and paclitaxel treatment , 2003, International journal of cancer.

[36]  Terukazu Nakamura,et al.  Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. , 2002, Cancer research.

[37]  S. Ozalp,et al.  Multidrug resistance gene-1 (Pgp) expression in epithelial ovarian malignancies. , 2002, European Journal of Gynaecological Oncology.

[38]  C. Tropé,et al.  A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. , 2002, European journal of gynaecological oncology.

[39]  F M Muggia,et al.  Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  G. Rustin,et al.  Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  S. Cannistra.  Medical progress : cancer of the ovary , 1993 .

[42]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[43]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .